GLP-1 & Hormone Therapy: Magic Duo
According to new research, menopause hormone therapy (MHT) may boost weight loss for postmenopausal women using GLP-1 drugs. These medications, such as tirzepatide and semaglutide, help manage obesity and type 2 diabetes.
Still, many postmenopausal women gain weight because of their hormones. This is because with estrogen loss comes slower metabolism, abdominal fat gain, and insulin resistance. Overall, these changes in the body can negatively impact the efficacy of weight loss drugs.
Currently, experts say that restoring estrogen levels may help postmenopausal women respond better to GLP-1s. In time, hormone therapy could dramatically enhance the weight loss possibilities for millions of women.
Managing Menopausal Weight Gain
At the Endocrine Society’s July 12, 2025 meeting, researchers presented data from a real-world study of 120 postmenopausal women. Specifically, 40 women received both menopause hormone therapy and tirzepatide. Meanwhile, another 80 used tirzepatide alone.
After six months, women on the combo therapy lost about 17% of their body weight. On the other hand, those using only tirzepatide lost closer to 14%.
Even more striking was that 45% of women in the combo group lost at least 20% of their weight. In contrast, just 18% in the drug-only group reached that milestone.
“These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women,” researcher Dr. Regina Castaneda noted in a news report.
Hormone Therapy Ups Drug Effectiveness
So, why does hormone therapy boost weight-loss drugs? Estrogen plays a direct role in appetite and fat storage. Moreover, it helps regulate how the brain responds to GLP-1 signaling.
Therefore, adding back the hormone estrogen seems to intensify GLP-1’s appetite-suppressing effects. Hence, researchers believe this synergy is responsible for the better weight loss outcomes in the combo group.
Notably, the researchers also saw the same benefits in women who began MHT within 10 years of menopause.
Implications for Women’s Health
Overall, these findings could reshape treatment plans for postmenopausal women struggling with weight. Until now, some providers have hesitated to prescribe GLP-1s to older women due to factors such as hormonal resistance.
However, this research suggests MHT may remove this barrier. Consequently, women in menopause could benefit as much from GLP-1 therapy as younger patients.
In addition to weight loss, improving estrogen levels can reduce heart disease risk, preserve muscle, and improve insulin sensitivity. Thus, the benefits of this hybrid approach may extend well beyond the scale.
More Research Still Needed
Despite promising results, researchers urge caution, as the study was observational and has not yet undergone peer review.
Also, the researchers were not able to assess side effects in detail. GLP-1 drugs may cause nausea and gastrointestinal distress, while menopause hormone therapy can increase clotting risks in some patients.
In time, further trials will be necessary to confirm long-term safety and outcomes. Even so, these findings mark an important step forward in personalizing obesity treatment for postmenopausal women.
Outlook: Hormone Therapy & GLP-1s
Menopause hormone therapy may significantly enhance the effectiveness of GLP-1 drugs like tirzepatide. With more research, this combo could become a powerful strategy in managing postmenopausal obesity and metabolic health.
Photo: Freepik